Mokina, T V, Antipenko, E A, Gustov, A V · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2009
This study looked at whether a medication called adaptol might help people with chronic fatigue syndrome (ME/CFS) who also have reduced blood flow to the brain. Researchers gave some patients adaptol while others received a comparison treatment, and they measured changes in fatigue and other symptoms. The study suggests adaptol may have helped improve some symptoms in this specific group of patients.
Most ME/CFS treatment research focuses on psychological or behavioral interventions; pharmacological trials exploring potential mechanisms like cerebral blood flow are relatively rare. This study addresses the intersection of ME/CFS and cerebrovascular dysfunction, which may represent a distinct patient subgroup requiring tailored therapeutic approaches.
This study does not establish that adaptol is effective for all ME/CFS patients, only potentially for those with documented chronic cerebral ischemia. The lack of published full-text data limits assessment of effect size, safety profile, and whether improvements were clinically meaningful. Findings cannot determine causation between cerebral blood flow reduction and ME/CFS symptoms.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →